Prescient Therapeutics Limited (PTX) AI Stock Analysis

Prescient Therapeutics Limited reported that 1,000,000 PTXAL options, exercisable at $0.412 and expiring on November 4, 2026, ceased after expiring without exercise or conversion. The lapse removes these securities from the company’s outstanding opti...

Prescient Therapeutics has reported the voting results of its 2026 Annual General Meeting, with shareholders approving the adoption of the remuneration report and endorsing the re-election of directors Dr Ellen Feigal and Dr Gavin Shepherd. However,...

Prescient Therapeutics Limited is an Australian oncology-focused biopharmaceutical company advancing targeted cancer therapies. Its lead asset, PTX-100, is being developed for T-cell lymphomas, including cutaneous T-cell lymphoma, with a growing glob...

Prescient Therapeutics reported that its Phase 2a trial of PTX-100 in relapsed or refractory cutaneous T-cell lymphoma has reached the enrolment threshold for its first Dose Optimisation Committee review, with 20 evaluable patients and 29 patients en...

Prescient Therapeutics director Dr Gavin Shepherd has increased his indirect shareholding in the company through an acquisition of 200,000 fully paid ordinary shares at $0.065 per share. The purchase, made via a trust in which he is a beneficiary, li...

Prescient Therapeutics reported a change in director Melanie Farris’s indirect holdings, reflecting her participation in the company’s Share Purchase Plan. Through Photo Genius Pty Ltd as trustee for The Farris Family Trust, Farris acquired 76,923 fu...

Prescient Therapeutics has reported a change in the holdings of director James Campbell following his participation in the company’s Share Purchase Plan. Campbell acquired 153,846 fully paid ordinary shares at $0.065 per share, increasing his direct...

Prescient Therapeutics has notified the market of the issue of 8,621,422 unquoted options, each exercisable at $0.0975 and expiring on 29 September 2030. The new options, recorded as a separate class of securities, mark an additional layer of equity-...

Prescient Therapeutics Limited, an ASX-listed biotechnology firm developing therapeutic treatments, continues to leverage its public listing to support ongoing research and development activities and broader strategic initiatives.The company has appl...

Prescient Therapeutics has lodged an Appendix 2A with the ASX for the quotation of 73,816,973 new ordinary fully paid shares. The securities, issued as part of previously announced transactions, will expand the company’s quoted capital base, potentia...

Prescient Therapeutics Limited has announced a proposed placement of up to 18,518,453 ordinary fully paid shares on the ASX. The new securities, expected to be issued on 30 September 2026, represent a fresh capital raising that may support the compan...

Prescient Therapeutics Limited, an ASX-listed Australian biotechnology company, operates in the oncology segment, developing targeted cancer therapies intended to improve treatment outcomes for patients. Its strategic focus is on advancing its clinic...

Prescient Therapeutics Limited, an ASX-listed biotechnology company trading under ticker PTX, focuses on developing therapeutic products within the life sciences sector. The business leverages capital market mechanisms on the Australian Securities Ex...

Prescient Therapeutics has extended the closing date of its share purchase plan by three days to 5.00pm AEST on 18 September 2026, after some eligible shareholders reported delays in receiving documentation. The board reported strong participation so...

Prescient Therapeutics has updated its proposed securities issue announcement, confirming an extension to the closing date of its securities purchase plan for shareholders. The plan, first detailed in late August, will now remain open until 15 Septem...

Prescient Therapeutics has extended the closing date for its Share Purchase Plan, which aims to raise up to A$7 million, from 8 September to 15 September 2026 to give eligible shareholders more time to participate after delays in receiving documentat...

Prescient Therapeutics has reached a key enrolment milestone in its Phase 2a trial of PTX-100 for relapsed or refractory cutaneous T-cell lymphoma, with 20 evaluable patients now enrolled across two dosing arms. This triggers the first planned Dose O...

Prescient Therapeutics will host a live interactive shareholder briefing on 28 August, led by CEO James McDonnell, to discuss its current Share Purchase Plan, the intended use of proceeds, and practical details on how investors can participate. The b...

Prescient Therapeutics has opened a Share Purchase Plan to raise up to $7 million, offering eligible shareholders new shares at $0.065, an 18.8% discount to the 10-day VWAP and a 9.7% discount to the last traded price. The move follows a year of stro...

Prescient Therapeutics Limited has launched a share purchase plan as part of a broader capital raising, targeting up to $7 million by offering eligible shareholders up to $30,000 of new shares at $0.065 each. The plan could result in the issuance of...

Prescient Therapeutics Limited has announced a proposed issue of ordinary fully paid shares under a securities purchase plan to its existing shareholders. The plan allows for the issue of up to 107,692,308 new shares, with a record date of 24 August...

Prescient Therapeutics has launched a Share Purchase Plan to raise up to $7 million, offering new shares at $0.065 each, a discount to recent trading levels, to eligible shareholders on the register as of 24 August 2026. The funds will primarily supp...

Prescient Therapeutics Limited has lodged its annual corporate governance disclosures with the ASX, including an updated governance statement approved by the board and made available on its website in line with listing requirements. The biopharmaceut...